• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Private CNS Company Review 2012 Released by NI Research


News provided by

NI Research

Mar 08, 2012, 08:20 ET

Share this article

Share this article


CARDIFF, Calif., March 8, 2012 /PRNewswire/ -- NI Research, the publisher of independent and authoritative reviews of the neurotherapeutics area, has released the 2012 edition of the Private CNS Company Review. PCNS provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities.

"In an era where many major pharmaceutical companies are still trying to develop a coherent and effective strategy for neuroscience, much of the most creative and promising R&D for neurotherapeutics is being carried out by privately held companies. The 138 companies reviewed in PCNS cover the full gamut of innovation, from those addressing highly innovative albeit risky novel targets, to companies developing clinical-stage modifications of familiar mechanistic themes," notes Harry Tracy, PhD, President of NI Research (http://www.niresearch.com).  

"Not all of them are going to be productive; there is both excellence and mediocrity to be found in this group, but any large or midsize pharmaceutical company intending to participate in the next generation of neurotherapeutics must pay close attention to the programs in development by these firms. No other publication focuses on this area with the depth and comprehensiveness of PCNS; it is a unique resource for Business Development teams at companies of any size," said Tracy, who provides consultation services to the neuropharm industry.

The Table of Contents for the 2012 edition of the Private CNS Company Review:

Private CNS Company Fates/Casualties

Private CNS Company Destinations

Private CNS Company Funding 2011

Opportunities by Stage of Development

2012 PCNS Inflection Points

Top Five PCNS Partnering Opportunities

Four PCNS Subsets: Neurotrophic Factors, Novel Pain Mechanisms, Novel Antidepressants, Novel Schizophrenia Drug Mechanisms

Company Reviews:

Accera

AC Immune 

Acumen Pharmaceuticals

Adamas Pharmaceuticals

Aestus Therapeutics

Affectis Pharmaceuticals

Afferent Pharmaceuticals

Affiris

Afraxis

AgeneBio

American Life Science Pharmaceuticals

Archer Pharmaceuticals

Arcion Therapeutics

Ariel Pharmaceuticals

ArmaGen Technologies   

Astraea Therapeutics

AurimMed Pharma

AviNeuro

Avraham Pharmaceuticals

Axerion Therapeutics

Axon-Neuroscience

Azevan Pharmaceuticals 

Bayhill Therapeutics   

BioArctic Neuroscience 

BioAxone BioSciences

BioChromix Pharma

Biocrea

BrainCells 

BrainTact

Cambria Pharmaceuticals

Canbex Therapeutics

Cara Therapeutics

CeNeRx BioPharma     

Cerecor

Ceregene

Chaperone Therapeutics

Clera

Cognition Therapeutics

Cognosci

Collegium Pharmaceuticals

CoLucid   

CoMentis

Convergence Pharmaceuticals

Cortica Neuroscience

Cyrenaic Pharmaceuticals

Dart Neuroscience/Helicon Therapeutics

Domain Therapeutics

Embera Neurotherapeutics

ENKAM Pharmaceuticals

EnVivo Pharmaceuticals 

Envoy Therapeutics

Euthymics Bioscience 

Galantos Pharma

Galenea   

GeNeuro

Hermo Pharma  

Insero Health

Intra-Cellular Therapies  

Karuna Pharmaceuticals

KeyNeurotek

Knopp Biosciences

Kyalin Biosciences

Maas Biolab

Mapreg

Marinus Pharmaceuticals

Medeia Therapeutics

MedGenesis Therapeutix

MediProPharma

Mind-NRG

Mithridion

Mnemosyne

M's Science

MSI Methylation Sciences

Naurex

Nautilus Neurosciences

Neuraltus

NeurAxon

Neurim

Neurimmune Therapeutics

NeuroGeneration

Neurogenetic Pharmaceuticals

NeuroHealing  

NeuroKin

NeuroKos

Neurolixis

Neurona Therapeutics

Neuronascent   

NeuroNova   

NeuroP

NeuroPhage 

NeuroPore Therapies

Neurotez

NeuroTherapeutics Pharma

Neurotune 

New World Laboratories

NoNO Inc.

Noscira

NsGene

Oligomerix

Pharmacofore

PharmaNeuroBoost

PharmatrophiX

Pharmaxon 

Pharnext

Prexa Pharmaceuticals

Probiodrug

ProMentis Pharmaceuticals

Proneuron Biotechnologies

Proteostasis Therapeutics

Psyadon Pharmaceuticals

Q Therapeutics

QR Pharma

Receptos

Regenesance

Remedy Pharmaceuticals

ReMYND

ReXceptor

Sage Therapeutics

SanBio

Satori Pharmaceuticals

SCT Spinal Cord Therapeutics

Seaside Therapeutics    

Senexis

SenexTa Therapeutics

Sinapis Pharma

SMART Biosciences

Somnus Therapeutics

Sonexa Therapeutics

Spinifex Pharmaceuticals

Synchroneuron

TauRx

TauTaTis

TheraQuest Biosciences

to-BBB

Trigemina

Trophos    

Xenome Ltd

Zenobia

On the Cusp ...

Programs by Company, Indication, Stage

Company Funding

VC CNS Portfolios

Private CNS Company Review 2012 is the annual, independent review of the private neuroscience company universe. The cost of PCNS 2012 is $4,000 for NeuroPerspective subscribers, $5,000 for nonsubscribers. Startup companies can contact us for pricing options.

About NI Research

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.

For information, go to http://www.niresearch.com

Blog: http://neurogram.wordpress.com

SOURCE NI Research

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.